Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

19.1%

61 terminated/withdrawn out of 319 trials

Success Rate

73.7%

-12.8% vs industry average

Late-Stage Pipeline

5%

15 trials in Phase 3/4

Results Transparency

1%

2 of 171 completed trials have results

Key Signals

63 recruiting2 with results53 terminated8 withdrawn

Enrollment Performance

Analytics

N/A
78(77.2%)
Phase 3
8(7.9%)
Phase 2
7(6.9%)
Phase 4
7(6.9%)
Phase 1
1(1.0%)
101Total
N/A(78)
Phase 3(8)
Phase 2(7)
Phase 4(7)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (319)

Showing 20 of 319 trials
NCT06723717Phase 2Recruiting

Efficacy of Daily IV Administration of Dornase Alfa up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence at 6 Months

Role: lead

NCT02890641Recruiting

Genetic and Electrophysiologic Study in Focal Drug-resistant Epilepsies

Role: lead

NCT02886650Not ApplicableCompleted

Impact of Thermocoagulation During Invasive EEG Monitoring in Children With Focal Drug-resistant Epilepsies

Role: lead

NCT03359434Completed

Blood Pressure Measurement Methods and Prediction of Intracranial Hemorrhage After Thrombectomy in Stroke

Role: lead

NCT03265860Completed

Intravoxel Incoherent Motion Prognostic Value in the Initial Evaluation of Patients With Acute Ischemic Strokes Using 3 Tesla Magnetic Resonance Imaging

Role: lead

NCT04667078Phase 3Recruiting

REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts

Role: lead

NCT07433088Not ApplicableNot Yet Recruiting

Validation of Virtual Reality Tests for the Assessment of Patients With Age-related Macular Degeneration as Clinical Endpoints

Role: collaborator

NCT05041569Recruiting

Description of Lymphatic Damage in Encephalic Venous Thrombosis and Strictures in MRI a Reverse-recovery Sequence: a Pilot Study

Role: lead

NCT04663399Recruiting

IMMunological resPonse Assessment afteR Acute iSchemic Stroke Treated With Endovascular Therapy (IMPRESS)

Role: lead

NCT02879071Recruiting

Long Term Follow-up After Embolization of Brain Arteriovenous Malformations

Role: lead

NCT06264531Phase 2Recruiting

Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations

Role: lead

NCT02878967Recruiting

Standardized Long Term Follow-up of Patients After Endovascular Embolization of a Brain Aneurysm

Role: lead

NCT04772963Recruiting

Genetics of Central Nervous System Arteriovenous Malformations (GENE-MAV)

Role: lead

NCT02896881Terminated

Interest of New MRI Sequences After Embolization of Brain Arteriovenous Malformations

Role: lead

NCT04971564Recruiting

Thrombo-inflammation Biomarkers Trial in Acute Cerebral Hypoxia

Role: lead

NCT02878915Not ApplicableCompleted

Ultrasound-guided Femoral Arterial Puncture for Interventional Neuro-radiology in Children

Role: lead

NCT02879123Recruiting

Early Neurological Clinical Recovery, 3 Months After Endovascular Treatment of an Acute Ischemic Stroke

Role: lead

NCT04785066Phase 2Completed

Efficacy of Pulmozyme® on Arterial Recanalization in Post-thrombectomy Patients Managed for Ischemic Stroke (NETs-target)

Role: lead

NCT02523261Not ApplicableCompleted

Interest of Direct Aspiration First Pass Technique (ADAPT) for Thrombectomy Revascularisation of Large Vessel Occlusion in Acute Ischaemic Stroke

Role: lead

NCT05999604Phase 3Recruiting

Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial

Role: lead